Eric Kerns1, David Rozansky, Megan L Troxell. 1. Department of Medicine, Division of Nephrology & Hypertension, Oregon Health & Science University, Portland, OR, USA.
Abstract
BACKGROUND: Complement 3 glomerulopathy (C3GN) is a newly proposed subcategory of glomerular disease with features including membranoproliferative glomerulonephritis (MPGN), C3-dominant immunofluorescent staining without appreciable immunoglobulin deposition, and electron-dense deposits. Aberrations of alternative complement pathway (AP) have been found in many C3GN patients. CASE-DIAGNOSIS/TREATMENT: A 13-year-old boy presented with edema in association with an upper respiratory infection. Studies demonstrated nephrotic syndrome with hematuria and markedly low C3 and C4. Initial renal biopsy showed MPGN with strong C3 and immunoglobulin deposition. The patient partially responded to immunosuppression. Follow-up biopsies at 10 months and 3 years demonstrated MPGN with strong C3, with little to no immunoglobulin deposition. Based on this and elevated SC5b-9, treatment was changed to eculizumab with further decrease in proteinuria. CONCLUSIONS: Serial biopsies illustrated marked variability in immunoglobulin deposition in MPGN with persistently strong C3 deposition. Whether this evolution was related to the course of disease or to therapeutic intervention, the pathologic progression documented in this series of biopsies challenges the newly proposed subcategories of MPGN.
BACKGROUND: Complement 3 glomerulopathy (C3GN) is a newly proposed subcategory of glomerular disease with features including membranoproliferative glomerulonephritis (MPGN), C3-dominant immunofluorescent staining without appreciable immunoglobulin deposition, and electron-dense deposits. Aberrations of alternative complement pathway (AP) have been found in many C3GN patients. CASE-DIAGNOSIS/TREATMENT: A 13-year-old boy presented with edema in association with an upper respiratory infection. Studies demonstrated nephrotic syndrome with hematuria and markedly low C3 and C4. Initial renal biopsy showed MPGN with strong C3 and immunoglobulin deposition. The patient partially responded to immunosuppression. Follow-up biopsies at 10 months and 3 years demonstrated MPGN with strong C3, with little to no immunoglobulin deposition. Based on this and elevated SC5b-9, treatment was changed to eculizumab with further decrease in proteinuria. CONCLUSIONS: Serial biopsies illustrated marked variability in immunoglobulin deposition in MPGN with persistently strong C3 deposition. Whether this evolution was related to the course of disease or to therapeutic intervention, the pathologic progression documented in this series of biopsies challenges the newly proposed subcategories of MPGN.
Authors: Leal C Herlitz; Andrew S Bomback; Glen S Markowitz; M Barry Stokes; R Neal Smith; Robert B Colvin; Gerald B Appel; Vivette D D'Agati Journal: J Am Soc Nephrol Date: 2012-06-07 Impact factor: 10.121
Authors: Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Ladan Zand; Nicole C Meyer; Nicolò Borsa; Samih H Nasr; Richard J H Smith Journal: Kidney Int Date: 2012-12-12 Impact factor: 10.612
Authors: Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Ladan Zand; Julie A Vrana; Samih H Nasr; Jason D Theis; Ahmet Dogan; Richard J H Smith Journal: Kidney Int Date: 2012-08 Impact factor: 10.612
Authors: Julianne Prasto; Bernard S Kaplan; Pierre Russo; Elaine Chan; Richard J Smith; Kevin E C Meyers Journal: Eur J Pediatr Date: 2014-01-03 Impact factor: 3.183
Authors: Hannah J Lomax-Browne; Nicholas R Medjeral-Thomas; Sean J Barbour; Jack Gisby; Heedeok Han; Andrew S Bomback; Fernando C Fervenza; Thomas H Cairns; Richard Szydlo; Sven-Jean Tan; Stephen D Marks; Aoife M Waters; Gerald B Appel; Vivette D D'Agati; Sanjeev Sethi; Cynthia C Nast; Ingeborg Bajema; Charles E Alpers; Agnes B Fogo; Christoph Licht; Fadi Fakhouri; Daniel C Cattran; James E Peters; H Terence Cook; Matthew C Pickering Journal: Clin J Am Soc Nephrol Date: 2022-07 Impact factor: 10.614
Authors: Cristina Rabasco; Teresa Cavero; Elena Román; Jorge Rojas-Rivera; Teresa Olea; Mario Espinosa; Virginia Cabello; Gema Fernández-Juarez; Fayna González; Ana Ávila; José María Baltar; Montserrat Díaz; Raquel Alegre; Sandra Elías; Monserrat Antón; Miguel Angel Frutos; Alfonso Pobes; Miguel Blasco; Francisco Martín; Carmen Bernis; Manuel Macías; Sergio Barroso; Alberto de Lorenzo; Gema Ariceta; Manuel López-Mendoza; Begoña Rivas; Katia López-Revuelta; José María Campistol; Santiago Mendizábal; Santiago Rodríguez de Córdoba; Manuel Praga Journal: Kidney Int Date: 2015-07-29 Impact factor: 10.612